201 related articles for article (PubMed ID: 15794384)
1. Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging.
Enzinger C; Strasser-Fuchs S; Ropele S; Kapeller P; Kleinert R; Fazekas F
Mult Scler; 2005 Apr; 11(2):135-9. PubMed ID: 15794384
[TBL] [Abstract][Full Text] [Related]
2. Conventional and advanced magnetic resonance imaging in tumefactive demyelination.
Saini J; Chatterjee S; Thomas B; Kesavadas C
Acta Radiol; 2011 Dec; 52(10):1159-68. PubMed ID: 22025739
[TBL] [Abstract][Full Text] [Related]
3. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
[TBL] [Abstract][Full Text] [Related]
4. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.
Malhotra HS; Jain KK; Agarwal A; Singh MK; Yadav SK; Husain M; Krishnani N; Gupta RK
Mult Scler; 2009 Feb; 15(2):193-203. PubMed ID: 19181773
[TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions.
Cha S; Pierce S; Knopp EA; Johnson G; Yang C; Ton A; Litt AW; Zagzag D
AJNR Am J Neuroradiol; 2001; 22(6):1109-16. PubMed ID: 11415906
[TBL] [Abstract][Full Text] [Related]
6. [A case of pediatric multiple sclerosis presenting with a tumefactive demyelinating lesion].
Majima H; Ito T; Koyama N
Rinsho Shinkeigaku; 2017 Feb; 57(2):88-91. PubMed ID: 28132974
[TBL] [Abstract][Full Text] [Related]
7. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy.
Cianfoni A; Niku S; Imbesi SG
AJNR Am J Neuroradiol; 2007 Feb; 28(2):272-7. PubMed ID: 17296993
[TBL] [Abstract][Full Text] [Related]
8. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R
Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455
[TBL] [Abstract][Full Text] [Related]
9. Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features.
Jain RS; Khan I; Kandelwal K; Desai T
Clin Neurol Neurosurg; 2017 Nov; 162():91-94. PubMed ID: 28987645
[TBL] [Abstract][Full Text] [Related]
10. Tumefactive demyelinating lesions.
Dagher AP; Smirniotopoulos J
Neuroradiology; 1996 Aug; 38(6):560-5. PubMed ID: 8880719
[TBL] [Abstract][Full Text] [Related]
11. Monophasic, solitary tumefactive demyelinating lesion: neuroimaging features and neuropathological diagnosis.
Tan HM; Chan LL; Chuah KL; Goh NS; Tang KK
Br J Radiol; 2004 Feb; 77(914):153-6. PubMed ID: 15010391
[TBL] [Abstract][Full Text] [Related]
12. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
[TBL] [Abstract][Full Text] [Related]
13. Tumefactive demyelinating lesions: A comprehensive review.
Algahtani H; Shirah B; Alassiri A
Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
[TBL] [Abstract][Full Text] [Related]
14. MRI Findings in Tumefactive Demyelinating Lesions: A Systematic Review and Meta-Analysis.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
AJNR Am J Neuroradiol; 2018 Sep; 39(9):1643-1649. PubMed ID: 30115676
[TBL] [Abstract][Full Text] [Related]
15. Tumefactive Multiple Sclerosis Masquerading as High Grade Glioma.
Lin M; Reid P; Bakhsheshian J
World Neurosurg; 2018 Apr; 112():37-38. PubMed ID: 29331745
[TBL] [Abstract][Full Text] [Related]
16. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study.
Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A
Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670
[TBL] [Abstract][Full Text] [Related]
17. Tumefactive demyelinating lesion: experience with two unusual patients.
Sinha MK; Garg RK; Bhatt ML; Chandra A
J Postgrad Med; 2010; 56(2):146-9. PubMed ID: 20622396
[TBL] [Abstract][Full Text] [Related]
18. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging.
Kim DS; Na DG; Kim KH; Kim JH; Kim E; Yun BL; Chang KH
Radiology; 2009 May; 251(2):467-75. PubMed ID: 19261924
[TBL] [Abstract][Full Text] [Related]
19. Demyelinating lesions behaving like aggressive tumours on advanced MRI techniques.
Barbosa BC; Marchiori E; Leal Leidersnaider C; Brandao L; Castillo M
Neuroradiol J; 2019 Apr; 32(2):103-107. PubMed ID: 30667319
[TBL] [Abstract][Full Text] [Related]
20. Local magnetization transfer ratio signal inhomogeneity is related to subsequent change in MTR in lesions and normal-appearing white-matter of multiple sclerosis patients.
Chen JT; Collins DL; Freedman MS; Atkins HL; Arnold DL;
Neuroimage; 2005 May; 25(4):1272-8. PubMed ID: 15850745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
